Slide 1: Corrigendum - Investor Presentation letter to exchanges
Cipla 29 th July, 2022 (1) BSE Ltd. (2) National Stock Exchange of India Ltd . Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Dalal Street Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip
Slide 2: Investor Presentation Q1FY23
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q1FY23 29-7-2022
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: Q1FY23 Performance: Key Highlights
Q1FY23 Performance CLICK Sustained TO EDIT performance MASTER across TITLEand geographies STYLE continued momentum on core profitability KEY HIGHLIGHTS Overall Revenue EBITDA R&D Investment1 INR 5,375 Cr INR 1,143 Cr Core margin trajectory intact; INR 274 Cr despite sharp 2% 6% 21.3% normalisation i
Slide 5: Continued focus on maintaining strong balance sheet health and robust free cash flow generation
Continued focus on maintaining strong balance sheet health and CLICK robust freeTO EDITflow cash MASTER TITLE STYLE generation Total Debt1 (INR Cr) Cash Balances2 Net Cash3 / Equity (INR Cr) 0.19 0.19 1,084 5,211 4,965 1,056 Mar'22 Jun'22 Mar'22 Jun'22 Mar'22 Jun'22 ▪ Robust free cash flow generatio
Slide 6: Financial Performance – Q1FY23
Financial Performance – Q1FY23 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,375 Cr 2% YoY EBITDA INR 1,143 Cr │ 21.3% 15% YoY Q1 FY23 (Consolidated) Revenue1 Break-up Actuals API, 3% vs Q1 FY 22 Others, 1% (INR Cr) International Total Revenue from Markets, 5,375 -2% 13% Operations EBITDA 1,143 -1
Slide 7: One India (Rx + Gx + CHL): Continued core portfolio momentum
One India (Rx + Gx+ CHL1): Continued core portfolio momentum across CLICKamid businesses TO EDIT MASTER significant TITLE STYLE normalisation in covid contribution Core One-India portfolio growth tracking above 10% for most quarters; market beating growth in branded prescriptions for 5 consecutive q
Slide 8: Strategic product deals and investments in Q1FY23
Strategic product deals and investments in Q1FY23 CLICK Continued TO EDIT MASTER strengthening TITLEfranchise of One-India STYLE with medium to long term growth levers Diagnostics Transaction description: Acquisition of 21.05% for ~INR 25 Cr. in Achira Labs, engaged in development and commercializat
Slide 9: Global consumer wellness franchise
Global consumer wellness franchise committed to provide a holistic CLICKsolutions; wellness TO EDIT MASTER TITLEhealth improving STYLE outcomes Consumer franchise in India Flagship Brands 1,100 INR Cr+ 9% Trailing 12-month revenue ↑ 22% ↑ 22% ↑ 18% ↑ 25% Contribution of Global Consumer franchise to
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access CLICK TO EDIT MASTER TITLE STYLE $ Mn South Africa2 Q1 Y-o-Y 8 ❖ Muted growth in private primary sales with recovery Brands launched expected in Q2FY23; traction in tender business across multiple ❖ In secondary terms, strong demand con
Slide 11: North America: Core formulation business continues steady momentum
North America: Core formulation business continues steady CLICK TOcontinued momentum; EDIT MASTER TITLE STYLE across categories serviceability North America 10% Steady momentum in core formulation business led by contribution from respiratory and peptide $ Mn Q1FY23 YoY growth assets amongst others
Slide 12: North America: Respiratory, Complex generics & Peptide pipeline
North America: Respiratory, Complex generics & Peptide pipeline CLICK TO EDIT MASTER TITLE STYLE Formulation / Brand name Pre-clinical Phase 1 Phase 2 Phase 3 Filed Approved Status Complex inhalation asset Filed in Q4FY20 Fluticasone + Salmetrol DPI Filed in Q1FY21 (gAdvair Diskus®) Respiratory Part
Slide 13: ANDA & NDA Portfolio & Pipeline (As on 30th June 2022)
ANDA1 & NDA Portfolio & Pipeline (As on 30th June 2022) CLICK TO EDIT MASTER TITLE STYLE 15 61 9 5 18 7 79 3 1 41 6 8 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs/NDAs 164 18 71 253 Approved Tentatively Under Approval Total ANDAs
Slide 14: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn Q1 Y-o-Y $ Mn Q1 Y-o-Y 18% 93 79 41 -57% 17 Q1FY22 Q1FY23 Q1FY22 Q1FY23 Key Business Highlights Key Business Highlights ❖ Strong DTM1 growth across geographies; ❖ Performance attributed to higher Q1FY22 off
Slide 15: Our Strategic Priorities for FY23
Our Strategic Priorities for FY23 CLICK TO EDIT MASTER TITLE STYLE Accelerate growth Building big prescription brands across Driving penetration and Consumer insighting driving portfolio in One-India chronic therapies, improved accessibility of brands for unmet expansion to address wellness needs en
Slide 16: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ankit Bhembre Investor.Relations@cipla.com For more information please visit www.cipla.com